Starling Oncology (STLNW) Receivables - Net (2020 - 2026)

Starling Oncology (STLNW) has reported Receivables - Net for 7 consecutive years, with $66.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net rose 19.21% year-over-year to $66.3 million; the trailing twelve-month figure through Jun 2026 stood at $66.3 million (up 19.21% YoY), and the FY2025 full-year result was $59.0 million, up 22.06% from the prior year.
• Receivables - Net advanced to $66.3 million in Q2 2026 per STLNW's latest filing, from $58.1 million in the prior quarter.
• Across five years, Receivables - Net topped out at $66.3 million in Q2 2026 and bottomed at $24.5 million in Q1 2022.
• Historically, Receivables - Net has averaged $48.6 million across 5 years, with a median of $48.9 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Receivables - Net surged 99.01% in 2022, then retreated 16.07% in 2025.
• Over 5 years, Receivables - Net stood at $39.8 million in 2022, then advanced by 6.39% to $42.4 million in 2023, then rose by 14.11% to $48.3 million in 2024, then grew by 22.06% to $59.0 million in 2025, then increased by 12.46% to $66.3 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $66.3 million, $58.1 million, and $59.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.